Destructive Mono-Arthritis Caused by <em>Mycobacterium bovis</em> during Treatment with Pembrolizumab in a Patient Previously Treated with BCG Instillations for Bladder Cancer: A Case Report
Cynthia Epskamp, Huijts Susanne M, Lubbe Peter AHM van der, Robbrecht Debbie G.J.
International Journal of Oncology Research · 2021-02
Abstract
Immune checkpoint inhibitor (ICI) treatment is an integral part of second line treatment of patients with urothelial carcinoma (UC) as well as in first line in cisplatin-ineligible patients with PD-L1 positive tumours. A substantial proportion of patients with bladder cancer have been treated with intravesical Mycobacterium bovis BCG in the past. Although it is rare, disseminated infections with Mycobacterium bovis have been described, but not in association with ICI treatment.
MeSH terms
- Mycobacterium bovis
- Pembrolizumab
- Medicine
- Bladder cancer
- Carcinoma
- Immunotherapy
- Immune system
- Cancer
- Internal medicine
- Oncology
- Immunology